FINAL ANALYSIS RESULTS AND PATIENT-REPORTED OUTCOMES FROM DESTINY-LUNG02-A DOSE-BLINDED, RANDOMIZED, PHASE 2 STUDY OF TRASTUZUMAB DERUXTECAN IN PATIENTS WITH HER2-MUTANT METASTATIC NSCLC
Giugno 9, 2026/da LuisaPREVALENCE AND REACTIVATION OF HEPATITIS B AND C IN PATIENTS UNDERGOING CHEMOTHERAPY FOR SOLID TUMORS.
Maggio 26, 2026/da LuisaERADICATION OF HELICOBACTER PYLORI IN THE PRIMARY PREVENTION OF GASTRIC CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
Maggio 19, 2026/da LuisaRISK OF BREAST CANCER AFTER OVARIAN CANCER IN WOMEN WITH A PATHOGENIC/LIKELY PATHOGENIC VARIANT IN BRCA1 OR BRCA2.
Maggio 12, 2026/da LuisaPEMBROLIZUMAB OR PLACEBO WITH CHEMORADIOTHERAPY FOLLOWED BY PEMBROLIZUMAB OR PLACEBO FOR NEWLY DIAGNOSED, HIGH-RISK, LOCALLY ADVANCED CERVICAL CANCER (ENGOT-cx11/GOT-3047/KEYNOTE-A18): A RANDOMISED, DOUBLE-BLIND, PHASE 3 CLINICAL TRIAL.
Maggio 5, 2026/da LuisaADJUVANT RIBOCICLIB PLUS NONSTEROIDAL AROMATASE INHIBITOR THERAPY IN PATIENTS WITH HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER: 5-YEAR FOLLOW-UP OF NATALEE EFFICACY OUTCOMES AND UPDATED OVERALL SURVIVAL.
Aprile 21, 2026/da LuisaROMIPLOSTIM VERSUS PLACEBO FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
Aprile 13, 2026/da Luisa22 GIUGNO 2026, PADOVA- PADUA MASTERCLASS IN NEURO-ONCOLOGY 2026
Aprile 8, 2026/da Luisa15 GIUGNO 2026-AIGOM LE NOVITA’ DA CHICAGO 2026: L’EVOLUZIONE DELLE CONOSCENZE IN ONCOLOGIA
Aprile 8, 2026/da LuisaAIGOM 2026: NOVITA’ NEL TRATTAMENTO DELLE NEOPLASIE GINECOLOGICHE, VERONA 21 APRILE 2026
Aprile 8, 2026/da Luisa18-19 MAGGIO 2026 RIMINI-CONVEGNO GRANDANGOLO IN ONCOLOGIA ONCOVISION 2026
Marzo 30, 2026/da LuisaTIME-OF-DAY IMMUNOCHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER: A RANDOMIZED PHASE 3 TRIAL.
Marzo 23, 2026/da Luisa
Scorrere verso l’alto
